Psoriatic Arthritis
Feature
After Yusimry’s steep discount, little clarity on future adalimumab biosimilar pricing
SmithRx, which bills itself as “next-generation pharmacy benefits management,” announced that it will offer Yusimry to its members at a discount...
Feature
Why not both? Dual biologics for treatment-resistant RA and PsA
Previous clinical trials of dual biologic therapies have raised safety issues, but more recent, promising findings from clinical trials and case...
Latest News
How does psoriasis affect fertility and birth outcomes?
“The mechanism to link the higher risk of pregnancy loss in patients with psoriasis is not clear,” the authors wrote.
Guidelines
EULAR PsA recommendations update emphasizes safety, nonmusculoskeletal manifestations
The update builds on 2019 recommendations and incorporates safety concerns about JAK inhibitors, advises on differential drug efficacy across...
Latest News
Cell activity in psoriasis may predict disease severity and provide clues to comorbidities
Skin samples from patients with psoriasis showed more fibroblast clusters in the upper layers of the skin in moderate to severe cases.
Commentary
A Joint Effort to Save the Joints: What Dermatologists Need to Know About Psoriatic Arthritis
Dermatologists are in a pivotal position to identify patients affected by psoriatic arthritis and start an appropriate systemic medication.
Practical Pearls
Glitter Effects of Nail Art on Optical Coherence Tomography
Optical coherence tomography (OCT) is a noninvasive imaging technology that can visualize nail morphology in diseases such as psoriatic arthritis...
Feature
Enthesitis, arthritis, tenosynovitis linked to dupilumab use for atopic dermatitis
Musculoskeletal symptoms identified in some patients treated with dupilumab for atopic dermatitis could help further understanding of how...
Conference Coverage
ILD risk elevated in RA, PsA after starting biologic or targeted synthetic DMARDs
The risk for interstitial lung disease in patients with PsA during the first 5 years after starting a biologic or targeted synthetic DMARD was...
News from the FDA/CDC
FDA approves Yuflyma as ninth adalimumab biosimilar
The manufacturer Celltrion is also seeking an interchangeability designation from the FDA, tentatively expected in the fourth quarter of 2024.
News from the FDA/CDC
FDA approves autoinjector pen for Humira biosimilar, Cyltezo
The drug will be commercially available on July 1, 2023.